InvestorsHub Logo
Followers 39
Posts 13438
Boards Moderated 2
Alias Born 12/09/2015

Re: 66Mustang post# 80285

Wednesday, 01/16/2019 7:59:44 AM

Wednesday, January 16, 2019 7:59:44 AM

Post# of 140510
Titan Medical's (TITXF) CEO David McNally on Q3 2017 Results - Earnings Call Transcript $TITXFhttp://www.seekingalpha.com/article/4124481

There is a consistent pattern of findings already emerging from our preclinical studies. First, we're being told by experienced robotic surgeons that the user requirements which we finalize in a milestone earlier this year are right on target. These surgeons are telling us that the system is useful in its present form as they've been able to perform the basic functions of surgery, including tissue manipulation and approximation, grasping, cutting, suturing, and coagulation with our advanced prototypes.

Throughout the year, we will continue to refine the system to optimize performance and manufacturability. And most significantly, we expect to prepare our regulatory submissions in the U.S. and Europe and to submit 510(k) and CE Mark applications before the end of 2018.